AILERON THERAP (NASDAQ:ALRN) Expected to Post Earnings of -$0.43 Per Share

Equities analysts expect AILERON THERAP (NASDAQ:ALRN) to report ($0.43) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for AILERON THERAP’s earnings, with the highest EPS estimate coming in at ($0.42) and the lowest estimate coming in at ($0.44). The business is expected to announce its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that AILERON THERAP will report full year earnings of ($1.63) per share for the current fiscal year, with EPS estimates ranging from ($1.79) to ($1.49). For the next financial year, analysts forecast that the business will post earnings of ($1.79) per share, with EPS estimates ranging from ($1.98) to ($1.61). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that cover AILERON THERAP.

Several analysts have weighed in on the stock. William Blair assumed coverage on shares of AILERON THERAP in a research note on Monday, July 24th. They issued an “outperform” rating for the company. Canaccord Genuity assumed coverage on shares of AILERON THERAP in a report on Monday, July 24th. They issued a “buy” rating and a $19.00 target price on the stock. Jefferies Group LLC assumed coverage on shares of AILERON THERAP in a report on Monday, July 24th. They issued a “buy” rating and a $20.00 target price on the stock. Finally, Bank of America Corporation assumed coverage on shares of AILERON THERAP in a report on Monday, July 24th. They issued a “buy” rating and a $19.00 target price on the stock.

In other news, insider Lilly Ventures Fund I. Llc bought 250,000 shares of the firm’s stock in a transaction on Wednesday, July 5th. The shares were purchased at an average cost of $15.00 per share, with a total value of $3,750,000.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Reinhard J. Ambros bought 266,667 shares of the firm’s stock in a transaction on Wednesday, July 5th. The stock was purchased at an average cost of $15.00 per share, for a total transaction of $4,000,005.00. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 696,667 shares of company stock worth $10,450,005. Insiders own 68.10% of the company’s stock.

An institutional investor recently bought a new position in AILERON THERAP stock. Candriam Luxembourg S.C.A. bought a new stake in shares of AILERON THERAP (NASDAQ:ALRN) during the second quarter, according to its most recent filing with the SEC. The institutional investor bought 150,000 shares of the company’s stock, valued at approximately $1,673,000. Candriam Luxembourg S.C.A. owned approximately 1.02% of AILERON THERAP at the end of the most recent reporting period.

Shares of AILERON THERAP (NASDAQ ALRN) opened at 12.73 on Monday. AILERON THERAP has a 52 week low of $10.73 and a 52 week high of $14.32. The company’s market capitalization is $187.26 million. The firm’s 50-day moving average is $12.92 and its 200 day moving average is $12.92.

ILLEGAL ACTIVITY NOTICE: This report was posted by [[site]] and is the property of of [[site]]. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at [[permalink]].

AILERON THERAP Company Profile

Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.

Get a free copy of the Zacks research report on AILERON THERAP (ALRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com